Arizona State Retirement System Reduces Stock Position in Kura Oncology, Inc. (NASDAQ:KURA)

Arizona State Retirement System lessened its position in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 8.2% during the 4th quarter, Holdings Channel reports. The firm owned 14,527 shares of the company’s stock after selling 1,296 shares during the quarter. Arizona State Retirement System’s holdings in Kura Oncology were worth $209,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. Tower Research Capital LLC TRC grew its stake in Kura Oncology by 46.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,710 shares of the company’s stock valued at $50,000 after purchasing an additional 1,501 shares during the last quarter. Royal Bank of Canada grew its stake in Kura Oncology by 81.5% during the 2nd quarter. Royal Bank of Canada now owns 6,801 shares of the company’s stock valued at $72,000 after purchasing an additional 3,053 shares during the last quarter. Pale Fire Capital SE purchased a new stake in Kura Oncology during the 3rd quarter valued at about $92,000. E Fund Management Co. Ltd. grew its stake in Kura Oncology by 12.2% during the 3rd quarter. E Fund Management Co. Ltd. now owns 11,929 shares of the company’s stock valued at $109,000 after purchasing an additional 1,301 shares during the last quarter. Finally, Point72 Middle East FZE purchased a new stake in Kura Oncology during the 4th quarter valued at about $115,000.

Insider Buying and Selling

In related news, SVP Thomas James Doyle sold 2,318 shares of the company’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $17.80, for a total value of $41,260.40. Following the completion of the transaction, the senior vice president now owns 48,093 shares of the company’s stock, valued at approximately $856,055.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Kura Oncology news, SVP Thomas James Doyle sold 2,318 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $17.80, for a total transaction of $41,260.40. Following the completion of the sale, the senior vice president now directly owns 48,093 shares in the company, valued at approximately $856,055.40. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Teresa Brophy Bair sold 2,053 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $17.80, for a total value of $36,543.40. Following the sale, the insider now owns 68,979 shares of the company’s stock, valued at $1,227,826.20. The disclosure for this sale can be found here. In the last 90 days, insiders sold 96,919 shares of company stock valued at $1,946,415. 5.40% of the stock is owned by company insiders.

Kura Oncology Stock Performance

NASDAQ KURA opened at $17.53 on Monday. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of -8.43 and a beta of 0.85. Kura Oncology, Inc. has a twelve month low of $7.41 and a twelve month high of $24.17. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 0.02. The stock has a 50-day moving average of $20.78 and a 200 day moving average of $15.28.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.01. During the same period last year, the firm posted ($0.49) earnings per share. Sell-side analysts anticipate that Kura Oncology, Inc. will post -2.35 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

KURA has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of Kura Oncology in a research note on Wednesday, March 6th. Wedbush reissued an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a report on Wednesday, February 28th. StockNews.com cut Kura Oncology from a “hold” rating to a “sell” rating in a report on Monday, April 15th. Finally, JMP Securities boosted their price objective on Kura Oncology from $22.00 to $32.00 and gave the company a “market outperform” rating in a report on Wednesday, January 31st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Kura Oncology currently has an average rating of “Moderate Buy” and a consensus target price of $28.28.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.